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ABSTRACT
We report a 32-year-old man and his 59-year-old mother with a unique and extensive variant of Camurati-Engelmann disease (CED)
featuring histopathological changes of osteomalacia and alterations within TGFb1 and TNFSF11 encoding TGFb1 and RANKL,
respectively. He suffered leg pain and weakness since childhood and reportedly grew until his late 20s, reaching 7 feet in height.
He had deafness, perforated nasal septum, torus palatinus, disproportionately long limbs with knock-knees, low muscle mass, and
pseudoclubbing. Radiographs revealed generalized skeletal abnormalities, including wide bones and cortical and trabecular bone
thickening in keeping with CED, except that long bone ends were also affected. Lumbar spine and hip BMD Z-scores wereþ7.7
andþ4.4, respectively. Biochemical markers of bone turnover were elevated. Hypocalciuria accompanied low serum 25-hydroxyvitamin
D(25[OH]D)levels.Pituitaryhypogonadismandlowseruminsulin-likegrowthfactor(IGF)-1werepresent.Karyotypewasnormal.Despite
vitamin D repletion, iliac crest histology revealed severe osteomalacia. Exon 1 of TNFRSF11A (RANK), exons 2, 3, and 4 of LRP5, and all
coding exons and adjacent mRNA splice junctions of TNFRSF11B (OPG), SQSTM1 (sequestosome 1), and TNSALP (tissue nonspecific
alkaline phosphatase) were intact. His asymptomatic and less dysmorphic 501100 mother, also with low serum 25(OH)D, had milder
clinical, radiological, biochemical, and histopathological findings. Both individuals were heterozygous for a novel 12-bp duplication
(c.27_38dup,p.L10_L13dup)inexon1ofTGFb1,predictingfouradditionalleucineresiduesinthelatency-associated-peptide segmentof
TGFb1,consistentwithCED.ThesonwasalsohomozygousforasinglebasetransversioninTNFSF11,predictinganonconservativeamino
acid change (c.107C>G, p.Pro36Arg) in the intracellular domain of RANKL that was heterozygous in his nonconsanguineous parents.
This TNFSF11 variant was not found in the SNP Database, nor in published TNFSF11 association studies, but it occurred in four of the 134
TNFSF11 alleles (3.0%) we tested randomly among individuals without CED. Perhaps the unique phenotype of this CED family is
conditioned by altered RANKL activity.  2011 American Society for Bone and Mineral Research.
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Introduction
C
amurati-Engelmann disease (CED: OMIM #131300) was
characterized by Cockayne in 1920.
(1) In 1922, Camurati
suggested that the disorder was heritable.
(2) Seven years later,
Engelmann described the severe form.
(3) In 1948, Neuhauser
et al.
(4) coined ‘‘progressive diaphyseal dysplasia’’ to emphasize
the advancing diaphyseal hyperostosis, yet normal metaphyses
and epiphyses, seen radiographically.
Descriptions of approximately 200 CED patients
(5,6) show that
both genders equally and all races are affected.
(6) However, the
penetrance (including age of onset, rate of progression, and
CASE REPORT J JBMR
Received in original form April 27, 2010; revised form September 7, 2010; accepted October 22, 2010. Published online November 4, 2010.
Address correspondence to: Michael P Whyte, MD, Shriners Hospital for Children, 2001 South Lindbergh Blvd, St. Louis, MO, 63131 USA.
E-mail: mwhyte@shrinenet.org
Presented in part at the 30th Annual Meeting of the American Society for Bone and Mineral Research, September 12–16, 2008, Montreal, Canada (J Bone Miner Res.
23: S106, 2008).
For a Commentary on this article, please see Van Hul (J Bone Miner Res. 2011;26:918–919. DOI: 10.1002/jbmr.391).
Journal of Bone and Mineral Research, Vol. 26, No. 5, May 2011, pp 920–933
DOI: 10.1002/jbmr.283
 2011 American Society for Bone and Mineral Research
920clinical course) is inexplicably variable.
(7,8) Usually, CED manifests
during childhood with leg pain, limping or a broad-based and
waddlinggait, muscle wasting,fatigue, weakness,and decreased
subcutaneous fat in the limbs that can mimic a muscular
dystrophy.
(6) Severe CED features a characteristic marfanoid
(9)
body habitus, occasionally including tall stature,
(10,11) enlarged
head with a prominent forehead and proptosis, and thin and
disproportionately long limbs
(6) with palpably widened bones
and skeletal tenderness. Cranial nerve palsies
(12) or raised
intracranial pressure can also develop.
(13,14) Sometimes puberty
is delayed,
(13,15) and there may be secondary hypogonadism
(16)
and prolonged growth.
(6) Deafness is not uncommon.
(6,12) Hips
and knees can develop flexion contractures.
(9,15) Some patients
have Raynaud’s phenomenon, hepatosplenomegaly, and other
findings suggestive of vasculitis.
(17) Remission of symptoms has
been reported during adult life.
(13,18–20)
The principal radiographic finding in CED is hyperostosis of
major long bone diaphyses due to proliferation of osseous tissue
on periosteal and endosteal surfaces.
(4) Maturation of the new
bone accentuates the cortical thickening. The tibiae and femora
are most commonly involved; less frequently are the radii, ulnae,
humeri, and short tubular bones. Hyperostosis usually begins in
the diaphysis, is fairly symmetrical, and spreads slowly, some-
times to include the metaphyses.
(11,21–24) However, epiphyses
are characteristically spared.
(10,13,20,21,23,25) Typically, long bone
shafts gradually widen and develop irregular surfaces. Osteo-
sclerosis can also involve the skull and axial skeleton, including
clavicles, scapulae, and pelvis. In severely affected children,
nearly the entire skeleton is altered, and some areas appear
osteopenic.
(15,26,27) Bone scanning usually reveals increased
radionuclide uptake within active lesions,
(28) again sparing the
epiphyses.
(29) Substantial radioisotope accumulation with mini-
mal radiographic findings characterizes early and active
disease,
(30,31) yet some ‘‘carriers’’ manifest only bone scanning
abnormalities.
(32) Magnetic resonance imaging (MRI) shows no
marrow disturbance.
(33)
Electron microscopy of CED muscle may reveal myopathic and
vascular changes, including atrophy of type II fibers without
degenerative changes.
(5) Skeletal histopathology of CED features
new bone formation along diaphyses where nascent, disorga-
nized osseous tissue undergoes centripetal maturation and
incorporation into the cortex.
(34) Osteomalacia has not been
reported.
(20)
Routine biochemical parameters of mineral homeostasis are
typically normal in CED, although markers of bone turnover,
(35)
including serum alkaline phosphatase (ALP), can be ele-
vated.
(19,34) When present, modest hypocalcemia and significant
hypocalciuria seem to reflect a markedly positive calcium
balance.
(19) Mild anemia, leukopenia, and elevated erythrocyte
sedimentation rate (ESR) are consistent with a systemic
disturbance.
(17) CED can respond to glucocorticoids,
(6,36–39)
showing diminution of bone pain and correction of histological
abnormalities in bone when small doses of prednisone are given
on alternate days.
(36,38,40) The clinical and laboratory findings in
severe CED, and the disorder’s responsiveness to glucocorticoid
therapy, indicate an inflammatory connective tissue disease.
(17)
Dihydrotachysterol treatment has also been beneficial.
(24)
Various bisphosphonates may help,
(41) but more likely will
not,
(14,26) and they are known to have exacerbated CED bone
pain.
(27,42)
In 2000, the cause of CED was discovered to be mutation
withinoneregion(thelatency-associated-peptide portion)ofthe
gene that encodes transforming growth factor b1( TGFb1).
(43,44)
These mutations in TGFb1 seem to enhance TGFb1 anabolic
effects within bone by freeing TGFb1 from the latency-
associated-peptide (see Discussion).
(6) To date, 10 distinctive
mutationsin thisdomain havebeen identified.
(6,30)Nevertheless,
there is evidence for locus heterogeneity causing CED.
(45)
Wereport amotherandadult sonwithauniquevariantofCED
featuring a generalized skeletal disorder with the histopatho-
logical characteristics of osteomalacia and alterations in two
genes that importantly regulate skeletal homeostasis: TGFb1
and TNFSF11, encoding TGFb1 and RANK ligand (RANKL),
respectively.
Materials and Methods
Family report
The propositus and each of his parents gave written informed
consent to be studied, as approved by the Human Research
Protection Office, Washington University School of Medicine, St.
Louis, MO.
Patient 1 (son)
This exceptionally tall 32-year-old white man, an only child, was
self-referred in 2007 to diagnose his skeletal disease. He was
accompanied by his nonconsanguineous parents.
At birth, he was full-term, delivered vaginally, and weighed 7
pounds, 13 ounces (50th percentile) and was 21.5 inches long
(90th percentile).
Hewaswelluntilapproximatelyage10years,whenhismother
noted that his ankles became pronated and flat feet ‘‘appeared
overnight.’’ His limbs then grew disproportionately long, and he
experienced difficulty running and keeping up ingym class. Both
legs ached at night. Several physicians had said that radiographs
showed osteopathia striata.
He reported that hegrewuntil atleastage 24 years,reaching 7
feet tall, and that an endocrinologist had excluded acromegaly.
His physes were said to be open in his late 20s, but growth charts
and radiographs from that time were not available. Knock-knees
with flexion contractures caused an arduous and shuffling gait.
He could walk barefoot for 10minutes before his knees and
ankleshurt. Painpersisted inhisfeet despiteshoeorthotics.After
prolonged sitting, his ankles would swell ‘‘over his shoes.’’ Mobic
(meloxicam), taken until one year earlier, improved his mobility,
generalized soreness, flexibility, and periodic leg, shoulder, and
back pains. Ibuprofen was almost as effective.
His mother reported that he had had finger clubbing since
childhood, but there did not seem to be a cardiopulmonary
explanation, in that he had a normal echocardiogram and no
pulmonary symptoms.
At age 26 years, deafness was discovered, and hearing aids
helped thereafter.
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changed during the past five years. Constant ‘‘sinus congestion’’
was worse in the morning.
Physical examination revealed an exceptionally tall and thin
man with knock-knees and hip and knee contractions that
caused stooped posture (Fig. 1). Nevertheless, his height was 6
feet, 10 inches (Z-scoreþ4.5) measured using a Harpenden
stadiometer (Holtain, Crymmych, UK). Arm span measured 6feet,
9 inches (reduced by slight elbow contractures), sitting height 3
feet, 1 inch (Z-score 0), and head circumference 59cm (  92%).
Limbs were disproportionately long with little muscle mass.
Weight was 187 lb (body mass index [BMI] 18.6kg/m
2). His face
was not dysmorphic, but facial hair was minimal (Fig. 1). His jaw
was not broad or prognathic, yet there was a torus palatinus. The
teeth were carious, and there was gingivitis. A prominent
perforated nasal septum (no history of trauma or cocaine use)
involved the inferior cartilaginous septum. With hearing aids, he
perceived tuning fork vibration better on the left. No tenderness
accompanied fist percussion over his spine or compression of his
ribs. His chest was not deformed. Forearms were broad from
expanded bones but nontender. His fingers had wider bones
than joints and considerable clubbing. His feet were remarkably
small for his extreme height (shoe size 11) (Fig. 1).
Otolaryngology consultation revealed narrow external audi-
tory canals, severe ossicular fixation, sensorineural hearing loss,
and minimal internal auditory canal narrowing with mild nerve
compression secondary to bone disease. A sleep study showed
severe periodic limb movement disorder accompanying his
history consistent with restless leg syndrome.
Patient 2 (mother)
This 59-year-old woman was discovered, following a car accident
in college, to have ‘‘strange bones.’’ A skeletal survey reportedly
showed ‘‘benign osteopathia striata,’’ but the radiographs could
not be located for review.
In high school she was thin and not athletic, with excessively
long lower limbs and little muscle mass. Menarche was at age 13
years, yet she reportedly grew until age 17 years, with irregular
periodsuntilstartingbirthcontrolpills.Menopausewasatage55
years.
She considered herself well and had not fractured. Some
increasing stiffness occurred with aging, primarily in her back,
hips, and lower limbs, including her knees. She, too, wore arch
supports. However, symptoms of arthritis occurred only in her
ankles, where swelling sometimes followed prolonged sitting.
Fig. 1. Patient 1 (son) (A,B) This 32-year-old, youthful-appearing, hypogonadal man stands 601000 tall and has disproportionately long arms and legs.
However, his upper segment is of normal size; the extremities are excessively long. (C,D) He has knock-knee deformity, relatively small feet, little muscle
mass,andwidebones.(E,F) Despitegeneralizedandsevereskeletaldisease, hisfaceis notdysmorphic.Hearingaidsarewornbilaterallyfordeafnesssince
age 26 years. (G) Pseudoclubbing has been apparent since childhood. (H) A torus palatinus (exostosis) is present (arrow).
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therapy. L4-L5 disc surgery helped back pain following a fall. She
recounted no finger clubbing, but there was expansion of the
proximal interphalangeal joints of her right hand. Her dentition
was good. She claimed only minimal hearing loss since age 50
years, but audiometry was>10 years previously. She wore
eyeglasses until successful Lasik surgery at age 40 years.
The subject had taken sulfasalazine for ulcerative colitis since
age30years,as wellasmacrodantin becauseofleukocytesinher
urine. She had not received glucocorticoids but took folic acid,
other vitamins, and fish oil for the colitis and sulfasalazine
treatment. She had taken a calcium supplement sporadically for
five years.
Physical examination revealed height of 5 feet, 10½ inches (Z-
scoreþ2.5) (Fig. 2). Her healthy sister was said to be 5 feet, 7
inches tall. Arm span was 5 feet, 11½ inches (Z-scoreþ2.8),
sitting height 2 feet, 11 inches (Z-score 0), head circumference
58cm (  90%), and weight 181 pounds. Torus palatinus was
present (Fig. 2). Teeth appeared well formed. She could hear a
softly ticking watch. No tenderness accompanied fist percussion
of her spine or femora, compression of her ribs, or gentle
squeezing of her forearms. Some tenderness occurred with
percussion of the pretibial regions. The distal tibias were
expanded with little overlying soft tissue. Feet were not flat.
Fingers showed some clubbing. Crepitus (2–3þ) occurred on
passive flexion and extension of her knees, but not with rotation
of the ankles.
Father
This 59-year-old man had no history of bone or joint complaints.
Height was 5 feet, 11 inches (Z-scoreþ0.4), arm span 6 feet,
2 inches (Z-scoreþ1.4). His sitting height and head circumfer-
ence were identical to his son’s.
Biochemical studies
Routinebiochemical studies were undertaken atthe Washington
University Medical Center, St. Louis, MO, and LabCorp (Kansas
City, MO, USA). Urine N-telopeptide (NTX) was measured at Mayo
Medical Laboratories, Rochester, MN, USA. At Shriners Hospital
for Children, St. Louis, MO, USA, assays included serum 25-
hydroxyvitamin D (25[OH]D; Immunodiagnostic Systems, Tyne
and Wear, UK), bone-specific ALP (BAP; Quidel Corp., San Diego,
CA, USA), osteocalcin (kit LKON1, Siemens Healthcare Diagnos-
tics, Los Angeles, CA, USA), and tartrate-resistant acid phospha-
tase (TRAP-5b;kit 8033,Quidel, Los Angeles,CA, USA).In2007, 15
healthy adults provided fasting serum to calculate reference
values (normal¼Nl) for these assays.
(46)
Radiological studies
We attempted to obtain all previous radiologic studies of our
patients for review. Mother and son underwent a limited
radiographicskeletalsurvey.DXAwasperformed usingaHologic
Fig. 2. Patient 2 (mother) (A) This 59-year-old woman is 501100 tall and has disproportionately long lower extremities, but less strikingly so than her son.
(B) Some muscle wasting is present, with wide bones at the ankles. (C) A torus palatinus (exostosis) is present (arrow).
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USA).
Iliac crest histology
Serum 25(OH)D was low in both son and mother, at 12 and
13ng/mL in the months of January and October, respectively
(30–100 Nl) (see below). The son, therefore, took one 50,000-unit
capsule of vitamin D2 (ergocalciferol) weekly for 6 weeks before
transiliac crest biopsy. The mother was not supplemented. Both
received two 3-day courses of tetracycline hydrochloride (250
q.i.d.), separated by approximately 2 weeks and ending 3 days
before biopsy using a Bordier 5mm internal diameter trephine.
Bone sections were stained with Goldner trichrome to identify
osteoid and osteoblasts, with von Kossa to distinguish calcified
from noncalcified bone (for better assessment for osteoid), and
unstained sections were used for fluorescence microscopy to
search for tetracycline labels.
Gene mutation studies
Genomic DNA was purified from blood leukocytes using the
Gentra Puregene DNA extraction kit (Invitrogen, Carlsbad, CA,
USA).
Exon 1 of TNFRSF11A, where activating duplications cause
familial expansile osteolysis and other allelic disorders that
resemble Paget bone disease,
(47) was amplified by PCR and
sequenced according to published methods.
(48) Exons 2, 3, and 4
of LRP5, where activating mutations cause a high-bone-mass
phenotype often associated with torus palatinus, were also
sequenced according to published methods.
(49) Furthermore, all
coding exons and adjacent mRNA splice sites of TNFRSF11B
(osteoprotegerin; OPG), TNFSF11 (RANKL), SQSTM1 (sequesto-
some 1), TNSALP (tissue nonspecific alkaline phosphatase), and
TGFb1 were amplified by PCR and sequenced in both directions
using published methods and primers
(50,51) and unpublished
primers (available on request) to search for mutations that cause
juvenile Paget disease, osteopetrosis, Paget bone disease,
hypophosphatasia, and CED.
DNA sequences were evaluated using AlignX software (Vector
NTI, Invitrogen, Carlsbad, CA, USA), and by inspecting individual
electropherograms.
Results
Biochemical findings
Biochemical testing of mineral and skeletal homeostasis
indicated accelerated bone turnover in both patients, but
especially in the son (Table 1).
Patient 1 (son)
Although serum 25(OH)D was initially low at 12ng/mL (30–100
Nl), total and ionized calcium, magnesium, PTH, and albumin
were normal (Table 1). Hypocalciuria was noted at<39mg/gm
creatinine (50–250 Nl). Serum ALP was elevated at 170 U/L (38–
126 Nl). His subnormal serum creatinine of 0.5mg/dL (0.7–1.5 Nl)
perhaps reflected low muscle mass. Plasma protein was slightly
elevated at 8.7g/dL (6.5–8.5 Nl). Serum total bilirubin was low at
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924 Journal of Bone and Mineral Research WHYTE ET AL.0.2mg/dL (0.3–1.1 Nl). Serum testosterone was deficient at
152ng/dL (241–827 Nl) while follicle stimulating hormone was
1.6IU/L(1.4–18Nlformen),prolactin5.2ng/mL(2.1–18.0Nl),and
17b-estradiol<40pg/mL (< 52 Nl for men). Serum random
growth hormone was elevated at 2.17ng/mL (0.01–0.97 Nl), but
IGF-1waslow at69ng/mL (115–307Nl)(MayoClinicDepartment
of Laboratory Medicine and Pathology), suggesting under-
nutrition. However, serum ferritin was 66ng/mL (22–322 Nl).
Erythrocyte sedimentation rate (ESR) was 67mm/hr (0–12 Nl)
and serum C-reactive protein (CRP; high sensitivity) was 57mg/L
(> 10mg/L consistent with infection or inflammation). Anti-
nuclear antibody was negative.
Markers of bone turnover, including serum ALP, indicated
rapid skeletal remodeling (Table 1). Serum osteocalcin was
232pg/mL (3.1–13.7 Nl) and BAP was 87 U/L (15.0–41.3 Nl). Urine
NTX was 1225 nmol bone collagen equivalents (BCE)/mmol
creatinine (21–66 Nl). Significant hypocalciuria (see above) may
have reflected positive calcium balance from his skeletal disease
compounded by vitamin D deficiency. Although serum 25(OH)D
was initially low, it was 31ng/mL (30–100 Nl) after ergocalciferol
supplementation at the time of iliac crest biopsy. Still, his urine
calcium remained undetectable.
Patient 2 (mother)
Although serum 25(OH)D was low at 13ng/mL (32–100 Nl), total
and ionized calcium, inorganic phosphate (Pi), PTH, and ALP
were normal (Table 1). A 24-hr urine collection contained 142mg
calcium (50–250 Nl); i.e., 115mg calcium/gm creatinine in
keeping with sequential DXA studies that indicated stable BMD
(see below).
Serum osteocalcin was elevated at 63ng/mL (9–47 Nl),
including a subsequent measurement at Shriners Hospital of
45ng/mL (3–14 Nl). Urine NTX was high at 99 nmol BCE/mmol
creatinine (19–63 Nl).
Serum creatinine, prolactin, T4, and TSH were normal (Lab
Corp, Kansas City, MO). Her ESR was 23mm/hr (0–35 Nl) and CRP
was 1.9mg/L (0–3 Nl).
Radiological findings
Findings are reported per patient and anatomic region.
Patient 1 (son)
Skeletal survey in 2007 showed abnormalities nearly throughout
the skeleton (Fig. 3).
The lateral skull had frontal calvarial thickening and sclerosis
producing frontal bossing. The parietal, temporal, and occipital
bones were largely spared, with only minimally increased
radiodensity, but the normal intramedullary space was absent
throughout the calvarium. Limited visualization of the facial
bones showed no sclerosis or deformity.
Anteroposterior and lateral radiographs of the cervical,
thoracic, and lumbar spine showed a common pattern of
abnormality involving the entirety of every vertebral segment.
The vertebral bodies were diffusely radiodense, with thickening
of the cortex of both the vertebral body proper and the posterior
elements. However, there was minimal enlargement of the
vertebralbodiesthemselvesandonlymoderateexpansionofthe
posterior elements. A common pattern of marked trabecular
thickening was present within the medullary space of the
vertebral bodies and the posterior elements, producing coarse,
thick, vertically oriented trabeculae in a pattern reminiscent of
vertebral hemangiomas. The cortical and trabecular changes
werenotassociatedwithsignificantscoliosisorkyphosis,andthe
intervertebral disk spaces in the cervical and thoracic spine
remainednormal.Disknarrowingindicativeofdiskdegeneration
was noted at L4-L5 and L5-S1. No evidence of marginal spurring
or facet arthritis was present. There was no indication of
spondyloarthritis.
A chest radiograph from 2001 also revealed diffuse osteo-
sclerosis. There was no indication of active cardiopulmonary
disease. Cortical and trabecular thickening was present
throughout the ribs, which were uniformly expanded. The
vertebral bodies were not enlarged, but they showed similar
thickening of the cortices and trabeculae. The findings in 2001
were unchanged in 2007.
Anteroposterior radiographs of the scapulae and pelvis,
including the sacrum, showed changes similar to the spine
with mild, diffuse bone expansion and cortical and trabecular
thickening. The thickened trabeculae followed normal stress line
patterns and were not as disorganized as typically seen in Paget
bone disease. Marked cortical thickening and uniform sclerosis
was particularly prominent in the superior and inferior pubic
rami, without the cortical splitting or ‘‘tram-tracking’’ of Paget
bone disease. Cartilage loss and spurring were present in both
hips, indicating moderate hip osteoarthritis.
Anteroposterior radiographs of the upper and lower extre-
mities showed similar changes throughout the long tubular
bones. There was diffuse bone expansion with cortical changes,
including thickening, periostitis more mature proximally than
distally, and coarsening of the medullary trabecular pattern most
prominent in the metaphyses and epiphyses. No significant
arthritic change was noted in the shoulders, elbows, wrists,
knees, or ankles. The bone shape was almost normal at the
epiphyses, where there was no expansion or deformity. Bone
expansion involved the short tubular bones of the hands, with
similar changes in the trabecular pattern, as seen in the long
tubular bones. Of particular note, the periostitis extended to the
ends of the long tubular bones in a pattern similar to primary
hypertrophic osteoarthropathy (pachydermoperiostosis), which
can be an autosomal dominant disorder affecting males more
severely than females.
(52) Autosomal recessive pachydermoper-
iostosis is the result of disturbances in prostaglandin metabolism
due to deactivating mutations in the gene that encodes 15-
hydroxyprostaglandin dehydrogenase.
(53)
DXA at age 32 years showed BMD Z-scores ofþ7.7 andþ4.4
in the patient’s L1-L4 spine and total hip, respectively. Although
these measurements can be influenced by large body size and
bone shaping, his sitting height and vertebral size were normal,
and therefore his vertebrae did seem to be genuinely dense.
In 2008, thin-section CT of the temporal bones was performed
bilaterally in the axial plane. Coronal sections of the paranasal
sinuses were also obtained. Diffuse thickening and sclerosis
was observed of all the visualized osseous structures of the
calvaria and facial bones. The temporal bones were diffusely
thickened and sclerotic, with a dysmorphic appearance. Under-
CAMURATI-ENGELMANN DISEASE Journal of Bone and Mineral Research 925Fig. 3. RadiographicfindingsofPatient1(son):Diffuseosteoslcerosisispresentthroughouttheskeleton.(A)Lateralradiographoftheskullatage32years
shows frontal calvarial thickening and sclerosis. The parietal, temporal, and occipital bones are largely spared. Normal intramedullary space is lost
throughout the calvarium. (B) Lateral radiograph of the chest shows cortical and trabecular thickening throughout uniformly expanded ribs. Vertebral
bodiesarenotenlargedbutshowsimilarthickeningofthecorticesandtrabeculaeandarediffuselyradiodense.(C,D)Thickeningofthecortexaffectsboth
the vertebral body and its posterior elements, but with minimal enlargement of the bodies and only moderate expansion of the posterior elements. A
sharedchangeaffects themedullaryspaceof the vertebralbodiesandtheir posteriorelements,producingcoarse, thick,vertically orientedtrabeculaein a
pattern reminiscent of vertebral hemangiomas. (E) Anteroposterior radiograph of the right hemipelvis shows changes similar to those in the spine, with
diffuse, mild bone expansion and cortical and trabecular thickening that follows normal stress line patterns, and are not as disorganized as seen in Paget
bone disease. Marked cortical thickening and uniform sclerosis is particularly prominent in the superior and inferior pubic ramus, with no cortical splitting
or ‘‘tram-tracking.’’ Cartilageloss and spurring in both hips indicates moderate osteoarthritis. (F-H) Anteroposterior radiographs of the upper (F) andlower
extremities (G,H) show similar changes throughout the long tubular bones. There is diffuse bone expansion with cortical changes including cortical
thickening, periosteitis that is more mature proximally than distally, and coarsening of the medullary trabecular pattern most prominent in the
metaphyses and epiphyses. Bone shape is almost normal at the epiphyses, where there is no expansion or deformity. No significant arthritic change was
notedintheshoulders,elbows,wrists,knees,orankles.Notably,theperiostitisextendstotheendsofthelongtubularbonesinapatternsimilartoprimary
hypertrophic osteoarthropathy (pachydermoperiostosis). Bone expansion also involves the short tubular bones of the hands with changes in the
trabecular pattern resembling the long tubular bones (not shown).
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partially fluid filled, likely representing chronic mastoiditis.
Minimal internal auditory canal narrowing occurred bilaterally.
Inner ear ossicles were normal. Narrowing and decreased space
within the middle ear cavity was due to dense osseous sclerosis.
The middle ear cavity was diminutive, given the adjacent
scleroticandthickenedtemporalbone.Thefacialcanals,cochlea,
and semicircular canals appeared normal. Dural walls were
thickened and sclerotic, but not to the severity of other calvarial
bones. The superior orbital fissures were patent bilaterally. The
frontal, ethmoid, sphenoid, and maxillary sinuses were clear.
Patient 2 (mother)
Radiographic skeletal survey of the mother in 2007 showed
findings that were in all ways similar to the son’s but generally
less severe(Fig.4). The overallpattern ofosteosclerosis andbone
expansion was present, although with better tubulation of the
long bones, less prominent trabecular thickening, and less
significant vertebral body change. The skull was unremarkable,
with no osteosclerosis and a normal medullary space. The short
tubular bones of the feet were involved, but there was less
immature periostitis over the long tubular bones, although the
mature periosteal reaction was again seen to extend to the
epiphysis. Like the son, the mother had changes of moderate,
bilateral hip osteoarthritis and early lumbar degenerative disk
disease. There was mild sacroiliac joint osteoarthritis but no
indication of spondyloarthritis. MRI of the lumbar spine from
2004 did not clarify the bone abnormality but documented
normal marrow, with no indication of a marrow infiltrative
disease.
DXA at age 60 years revealed BMD Z-scores ofþ2.6,þ4.4, and
–0.2 in her L1-L4 spine, total hip, and wrist, respectively.
Elsewhere, DXA (GE Lunar Corporation, Madison, WI, USA) had
showed little change in L1-L4 spine and femoral neck BMD
between ages 52 and 57 years.
Histopathology findings
Patient 1 (son)
Von Kossa–stained sections showed two thickened cortices with
very high porosity (Fig. 5A). Trabecular bone had very poor
connectivity.Therewasapaucityofbonemarrowelements.Both
von Kossa and Goldner trichrome–stained sections showed
extensive osteoid (Fig. 5A, B). In many places, the osteoid was
covered by plump, active-appearing osteoblasts. Osteoclasts
were also increased in some areas, most notably those without
osteoid, but had normal appearances. There was no osteitis
fibrosa. Fluorescence microscopy of an unstained section
showed broad, wide, predominantly single labels, while many
areas of osteoid showed no tetracycline labeling (Fig. 5C). Taken
together, the findings indicated severe osteomalacia.
Patient 2 (mother)
Transiliac crest biopsy with von Kossa–stained sections showed a
porous, thickened cortex and poor trabecular connectivity in the
Fig. 4. Radiographic findings of Patient 2 (mother) (A-F) The radiographic skeletal findings are in all ways similar to those of the son but are generally less
severe. The skull is normal, with no osteosclerosis and a normal medullary space. The overall pattern of osteosclerosis and bone expansion is present,
although there is less prominent vertebral body change and better tubulation of the long bones and less prominent trabecular thickening. There is less
immature periostitis noted along the long tubular bones, although the mature periosteal reaction is again seen to extend to the epiphysis. As in the son,
there are changes of moderate bilateral hip osteoarthritis and early lumbar degenerative disk disease.
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Increased osteoid was also observed on von Kossa and Goldner
trichrome–stained sections (Fig. 5D, E), which again was
somewhat less extensive than in the son. Fluorescence
microscopy of unstained sections showed more double labels
than those of the son, but also areas of broad single labels and
unlabeled osteoid indicating osteomalacia (Fig 5F).
Mutation analyses
No mutations were detected in the son’s genes encoding RANK,
OPG, LRP5, sequestosome 1, or TNSALP. However, in TGFb1,w e
found a novel 12-bp duplication (c.27_38dup, p.L10_L13dup) in
exon 1 that would insert four leucine residues into the latency-
associated peptide. This mutation was also detected in the
mother. The duplication was reminiscent of a report of a 9-bp
insertion at the same site, adding three leucine residues in a
patient with CED.
(44)
Additionally, we identified in the son’s TNFSF11 gene,
encoding RANKL, a homozygous, single-base alteration predict-
ing a nonconservative amino acid change (c.107C>G,
p.Pro36Arg) in RANKL that was heterozygous in both parents.
This TNFSF11 transversion was not found in dbSNP (SNP
Database),
(54) nor was it reported in several association studies
of RANKL polymorphisms.
(55–57) However, we found it in 4 of 134
TNFSF11 alleles (3.0%) tested randomly among our patients and
family members who did not have skeletal disorders resembling
CED.
(58)
Treatment
Patient 1’s symptoms did not change with ergocalciferol
supplementation and increases in serum 25(OH)D to>30ng/
mL. However, there was significant improvement with a tapering
course of prednisone that commenced with 40mg orally daily
(Howard Rosen, MD, personal communication). After several
Fig. 5. Histological findings: (A-C) The iliac crest specimens from patient 1 (son) and (D–F) patient 2 (mother). Overall, the findings were consistent with
osteomalacia that was more striking in the son. (A,D) Von Kossa–stained sections show thickened porous cortices and decreased trabecular connectivity.
(B,E) Goldner trichrome–stained sections show thick osteoid seams covering most trabecular and cortical surfaces. (C,F) Fluorescence microscopy shows
broad single tetracycline labels (arrowheads) as well as unlabeled osteoid (arrows). Although double tetracycline labels could be found in both patients,
they were more numerous in the mother (asterisk).
928 Journal of Bone and Mineral Research WHYTE ET AL.days, back pain resolved, after which he no longer used crutches
at home and stopped analgesic medications. An alternate-day
maintenance regimen of prednisone is a current goal for his
treatment.
Discussion
Wereportauniquedisorderaffectingamotherandheradultson
that is a variant of CED where essentially the entire skeleton
(including the ends of major long bones) is abnormal and
histopathological changes are consistent with osteomalacia. The
son’s condition is distinctly worse considering his clinical,
radiological,biochemical,andhistopathologicalfindings.Anovel
heterozygous TGFb1 duplication in keeping with CED was
identified in both individuals, but the son is also homozygous
and his mother heterozygous for a missense change in TNFSF11
encoding RANKL.
CED phenotype
The son manifests many of the typical features of CED reviewed
in the Introduction, and his digital clubbing,
(59) marfanoid body
habitus,
(9) flat feet, valgus ankles, and knock-knees sometimes
also occur in this disorder.
(15) Deafness, too, is prevalent with
skull base involvement and may reflect a sensorineural,
conductive,ormixedpathogenesis.
(60,61)Therecanbenarrowing
of (1) the internal auditory canals and bony encroachment on
nerves and vessels,
(60) (2) the tympanic cavities with fixation or
adhesion of ossicles, and (3) the bony part of the auditory tubes,
causing serous otitis media.
(60) Skeletal maturation can be
delayed.
(15) In 1964 Clauson and Loop
(15) reported a ‘‘tall’’ boy
whose growth plates were open and who was still growing at
age20 years. Wehave not, however, found reports ofperforation
of the nasal septum in CED.
The radiographic findings of CED were detailed by Neuhauser
et al. in 1948.
(4) Hyperostosis progresses from the diaphysis over
the long axis of tubular bones in both directions.
(4) Metaphyses
become widened, and the distal femur may develop an
Erlenmeyer flask deformity.
(11) Epiphyses are often broadened,
with flattening of the condylar surfaces at the knee. There is also
general widening of the articular surfaces of the hips and
elbows.
(4) CT shows that, along diaphyses, abnormalities are not
uniformly distributed.
(11) Endosteal alterations are more pro-
nounced than periosteal changes, and sclerosis is not homo-
geneous.
(11) Although longboneends aretypically spared by the
hyperostosis of CED, metaphyses and epiphyses may appear
osteopenic.
(15) Reports of epiphyseal involvement by osteo-
sclerosis are exceptional, but have included the femoral capital
epiphysis bilaterally and a proximal tibial epiphysis in a 73-year-
old man.
(62) Some authors conclude that epiphyses, indeed the
entire skeleton, can eventually become involved.
(6,15)
The radiographic pattern of our patients’ skeletal disorder is
not specific. Overall, it most closely resembles CED, with
symmetrical, generalized osteosclerosis and tubular bone
expansion primarily involving the metadiaphysis. However, the
findings include more prominent involvement of the flat bones
and spine, as well as more pronounced immature periostitis
extending to the ends of the tubular bones. Additionally, in the
son there is less well-developed medullary narrowing, more
prominent trabecular thickening, and more cranial vault
involvement than is typically seen in CED. The mother’s changes
are less striking.
Histological study of CED bone has shown thickened
periosteum and small blood vessel walls without inflammation.
The surface of lesional bone can consist of immature osseous
tissue
(63) where woven bone then undergoes maturation and
cancellouscompaction.
(34)Therecanbedense,subjacentcortical
bone with normal haversian systems and minimal osteoblastic
and osteoclastic activity.
(15,63,64) Osteoclasts may be few.
(40)
Marrow space can contain increased interstitial fibrosis.
(15)
Osteoid osteoma or chronic osteomyelitis have been diagnosed
in CED.
(65,66) In 2007, Bondestam et al.
(27) reported iliac crest
histology (following tetracycline labeling) of a 10-year-old boy
withCEDthatfeaturedtrabecularosteoporosiswithnormalbone
remodeling. Osteoporosis has been described by other patients
with CED,
(6) but we have not found a report of osteomalacia.
The principal histopathological abnormality of our patients’
iliac crest specimens was not anticipated. Changes consistent
with osteomalacia were documented in both individuals despite
elevated biochemical markers of bone turnover indicating
accelerated skeletal remodeling. The osteoid excess in the
specimens did not appear to be due to rapid bone turnover. We
saw primarily broad, single fluorescent labels as well as
unlabeled osteoid and verified that both subjects took the
tetracyclinehydrochloridecorrectly. VitaminDdeficiencydidnot
seem to explain their osteomalacia.
(67) Mother and son each had
a serum 25(OH)D level that might have been considered normal
until recently.
(67) Furthermore, their serum levels of calcium, Pi,
and PTH were unremarkable. Additionally, the son took 300,000
units of vitamin D2 orally over the six weeks leading up to his
biopsy, when he had a serum 25(OH)D level>30ng/mL. Serum
ALP activity and other markers of bone turnover were elevated,
especiallyintheson,perhapsoriginatingnotonlyfromincreased
skeletalmass,butalsofromregionselsewhereofenhancedbone
remodeling within lesional bone not captured by iliac crest
biopsy. In the son’s iliac crest specimen, pockets of normal-
appearing osteoclasts were seen on bone surfaces not covered
by osteoid, likely contributing to his especially elevated urine
NTX level. His hypocalciuria, before and after vitamin D2
supplementation, likely reflected positive bone balance, not
gastrointestinal malabsorption, although we do not have
sequential BMD measurements by DXA to verify this.
CED genetic defect
CED features variable penetrance and wide-ranging expressiv-
ity,
(6) even within families.
(6,7,66,68) Our patients’ disorder was
distinctly worse in the son. In 1997, Saraiva reported that the
severity of CED seems to depend on gender and parental
transmission, with males carrying a paternal mutation being
the most affected.
(66) In 2000, he
(69) suggested that genetic
‘‘anticipation’’ (disease severity increasing over generations)
might explain such variation. Perhaps gene repeat expansion,
enhanced somehow by father-to-son transmission, was the
mechanism.
(69) That same year, Makita et al.
(7) reported
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Japanese family with CED.
In 2000, discovery that TGFb1 mutation causes CED, together
withsubsequentfamilystudies,confirmedthedisorder’svariable
expressivity by documenting asymptomatic family mem-
bers.
(43,44) Following reports of higher plasma TGFb1 levels in
individuals with a -509T allele, Campos-Xavier et al.
(68) in 2001
investigated whether TGFb1 polymorphisms explain the variable
penetrance of CED. A seemingly unaffected 18-year-old girl in
the youngest generation of a Portuguese family
(68) carried their
R218H mutation in TGFb1. These investigators
(70) reported
significant intrafamilial variability for CED, including five
individuals within four families who did not have clinical
manifestations despite a TGFb1 mutation. No significant
association with polymorphisms was established among CED
families.
(68) In fact, two subjects with both the -509T poly-
morphism and a TGFb1 mutation showed either no clinical
symptoms or severe disease. In 2004, Wallace et al.
(6) also did not
find effects from TGFb1 polymorphisms. Perhaps CED variability
reflected modifying genes.
(6,68) In2006, Janssens et al.
(30) studied
24 CED families and noted that their types of TGFb1 mutation
would probably not cause anticipation. Instead, they suggested
that additional genetic factors, such as single nucleotide
polymorphisms (SNPs) in TGFb1 or alterations in other genes,
might modulate CED expressivity.
(30)
In fact, there may be CED variants without defects in TGFb1.I n
2002, Nishimura et al.
(9) proposed a second form of CED (CED
type II)featuring striations ofthe bones.For twounrelated 7-and
11-year-old Japanese girls with many clinical features of CED,
radiographs showed cortical thickening resembling CED but also
metaphyseal expansion of long bones; coarse and thick
trabeculae of the long and short tubular bones; striations in
the spine, pelvis, and long bones; and cranial sclerosis restricted
to the petromastoid region. These changes overall were
considered identical to the extremely rare disorder ‘‘hyperostosis
generalisatawithstriationsofthebones’’
(70)ratherthantoCED.
(9)
PCR direct sequencing of all exons and their flanking regions of
TGFb1 did not reveal mutations in these girls. Furthermore, PCR
single strand conformational polymorphism analysis of the TGF-
b type 1 receptor gene (TGFbR1) did not show any aberrant
DNA fragments. These authors concluded that their patients
represented a unique entity, CED type II.
(9)
Unlike in CED II, our patients have a distinctive TGFb1
mutation. Nevertheless, our cumulative findings support a
potential impact of modifying genes. Perhaps their RANKL
variant influences the CED phenotype and manifests an allele
dosage effect (see below).
TGFb1 function
TGFb1 features a unique expression structure encoding a
colinear protein from seven exons that must be cleaved into
two peptides: a latency-associated protein (LAP) encoded by
exons 1–5, and TGFb1 encoded by exons 6–7.
(71) Pre-pro-TGFb1
consists of a signal peptide (1aa–27aa), the LAP region (33aa–
252aa), and TGFb1 (293aa–390aa).
(71) The pro-TGFb1 precursor
molecule dimerizes and undergoes proteolytic cleavage to
separate the LAP and TGFb1 moieties. However, the LAP remains
associated in the bone matrix with mature TGFb1 until subjected
to specific activation conditions.
(30) Release of LAP activates
circulating TGFb1
(30) and presumably also TGFb1 within bone.
Then, free TGFb1 regulates bone cells
(6) in multiple ways.
TGFb1 stimulates skeletal turnover by increasing both bone
formation and resorption.
(6) In fact, biochemical markers of
skeletal remodeling were elevated in our patients. TGFb1
enhances the generation and activity of osteoblasts.
(6) Osteo-
clasts are affected by two pathways. TGFb1 directly promotes
their formation and activity, but also indirectly inhibits
osteoclastogenesis by increasing OPG and decreasing RANKL
expression in osteoblasts and stromal cell precursors.
(72,73)
Saito et al.
(74) reported increased proliferation of human
osteoblast MG-63 cells during coculture with CED fibroblasts,
suggesting mutant (R218H) TGFb1–stimulated osteoblast
growth. McGowan et al.
(75) used CED peripheral blood mono-
nuclear cells with a R218C mutation and noted 5-fold osteoclast
formation and 10-fold bone resorption that were inhibited by
soluble TGFb1 type II receptor. Therefore, these two missense
mutations (near the cysteine residues involved in LAP dimeriza-
tion)enhanceTGFb1effectsonbothosteoblasts andosteoclasts,
increasing bone turnover.
(6) Accordingly, CED mutations are
gain-of-function defects for the skeleton.
(75) TGFb1 can inhibit
some myogenic transcription factors and adipogenesis,
(76,77)
perhaps explaining the weakness and cachectic phenotype of
severe CED.
(27)
Our patients’ TGFb1 defect
All 10 TGFb1 mutations causing CEDinvolveLAP; noneare within
TGFb1 itself.
(6) They comprise a limited set of defects: (1) a three-
leucine insertion in the signal peptide (L10-L12dup), (2) a Y81H
missense mutation encoded in exon 1, (3) a R156C missense
mutation in exon 2, and (4) a group of at least seven missense
mutations (R218C, R218H, H222D, C223R, C223S, C223G, C225R)
in exon 4 at or near two cysteine residues involved in disulfide
bonding between the LAP homodimers.
(6,30) Because this last
groupofmutationstendstoclusterattheC-terminusofLAPnear
the site of interchain disulfide bonds coupling the LAP
homodimers,
(6) perhaps they disrupt LAP binding to TGFb1,
leading to increased release of active TGFb1 from cells.
(6)
Therefore, these heterozygous mutations seem to augment wild
type, functional TGFb1.
Our two patients have a heterozygous 12-bp duplication in
exon 1 of TGFb1, predicting a four-leucine duplication (L10-
L13dup) at the same site previously reported for the three-
leucine duplication.
(44) Cell culture studies showed that the L10-
L12dup mutation, which is in the signal peptide, seemed to
compromise secretion, causing intracellular accumulation of
TGFb1.
(71) This led to increased TGFb1 activity by a different
mechanism and potentially an alternative pathway, compared to
the missense mutations near the cysteine residues involved in
dimerization.
(71) The leucine duplication of our patients would
presumably function similarly in this second way.
Other genes
Patient 1 had periosteal new bone formation that extended to
the ends of his long tubular bones. This finding resembled
930 Journal of Bone and Mineral Research WHYTE ET AL.pachydermoperiostitis (OMIM %167100, #259100), where
clubbing and disproportionately long limbs can be a feature.
However, he had no characteristic skin changes or acro-
osteolysis, and we did not examine his 15-hydroxyprostaglandin
dehydrogenase gene; this gene encodes the principal enzyme
involved in prostaglandin degradation and is deactivated in
autosomal recessive pachydermoperiostitis (#259100).
(53)
Ghosal hematodiaphyseal dysplasia (OMIM #231095), an
autosomal recessive disorder due to loss-of-function mutations
in the TBXAS1 gene encoding thromboxane synthase,
(78) causes
refractory anemia and skeletal dysplasia affecting diaphyses and
metaphyses even more extensively than in CED.
(79) Thromboxane
synthase produces thromboxane A2 and thereby modulates
expression of RANKL (increases) and OPG (decreases).
(78) We did
not measure serum RANKL or OPG levels in our patients.
Our patients’ RANKL variant
InadditiontoadistinctiveTGFb1mutationcausingafour-leucine
duplication, patient 1 (the son) also carries a homozygous
missense variation (P36R) in RANKL. This TNFSF11 change was
not found in dbSNP
(54) and was not reported in several
association studies of RANKL SNPs with bone phenotypes.
(55–
57) The base change predicts a nonconservative amino acid
alteration in a conserved region of this molecule that regulates
osteoclastogenesis. RANKL is membrane bound, or soluble. P36
is part of an intracellular proline-rich region of RANKL (7 proline
residues per 10–amino acid stretch) near the plasma membrane.
The unique ring structure of proline gives it a special role in
polypeptide conformation, and some proline-rich regions form
important functional motifs; e.g., the 10–amino acid proline-rich
motifsinSrchomology3(SH3)bindingsites
(80)andaproline-rich
region of p53 required for apoptosis.
(81) However, we are
unaware of any distinctive function for this 10–amino acid
proline-rich region in RANKL. Alternatively, this transversion may
inhibitRANKLtraffickingtothecellmembrane,insertionthere,or
shedding (Dr. Christopher Nelson, personal communication). We
identified a single copy of this RANKL variant in four of 67
patients or their family members (134 alleles) with bone diseases
other than CED. Preliminary studies of a healthy population
detected the heterozygous change in 3 out of 103 individuals (3/
206 alleles) (Mumm and Villareal, unpublished). Accordingly, this
missense change may represent a relatively rare RANKL
polymorphism that conditions the CED phenotype of our two
patients. In fact, patient 1 is homozygous for this RANKL change
and is more severely affected than his heterozygous mother.
Perhaps this exemplifies the influence of ‘‘other’’ genes on the
variableCEDphenotype,includinganalleledosageeffectofsuch
an additional gene(s). It is not understood, however, how the
novel TGFb1 defect, and perhaps RANKL change, causes this
unique variant of CED with widespread skeletal disease and
histopathological changes of osteomalacia.
Disclosures
All authors state that they have no conflicts of interest.
Acknowledgments
AngeliaEnglishandSharonMcKenzieprovidedexpertsecretarial
help. Vivienne Lim and Dawn Russell helped to illustrate the
manuscript.
The project was supported by Shriners Hospitals for Children,
the Clark and Mildred Cox Inherited Metabolic Bone Disease
Research Fund, the Hypophosphatasia Research Fund, the
Barnes-Jewish Hospital Foundation, and by award number
R01DK067145 from the National Institute of Diabetes and Diges-
tive and Kidney Diseases. The content is solely the responsibility
of the authors and does not necessarily represent the views of
the National Institute of Diabetes and Digestive and Kidney
Diseases or the National Institutes of Health.
References
1. Cockayne EA. Case for diagnosis. Proc R Soc Med. 1920;13:132–136.
2. Camurati M. Di uno raro caso di osteite simmetrica ereditaria degli
arti inferiori. Chir Organi Mov. 1922;6:662–665.
3. Engelmann G. Ein fall von osteopathia hyperostotica (sclerostisans)
multiplex infantilis. Fortschr Roentgenstr. 1929;39:1101–1106.
4. Neuhauser EB, Shwachman H, Wittenborg M, Cohen J. Progressive
diaphyseal dysplasia. Radiology. 1948;51:11–22.
5. Naveh Y, Kaftori JK, Alon U, Ben-David J, Berant M. Progressive
diaphyseal dysplasia: genetics and clinical and radiologic manifesta-
tions. Pediatrics. 1984;74:399–405.
6. Wallace SE, Lachman RS, Mekikian PB, Bui KK, Wilcox WR. Marked
phenotypic variability in progressive diaphyseal dysplasia (Camurati-
Engelmann disease): report of a four-generation pedigree, identifica-
tion of a mutation in TGFB1, and review. Am J Med Genet A.
2004;129A:235–247.
7. Makita Y, Nishimura G, Ikegawa S, Ishii T, Ito Y, Okuno A. Intrafamilial
phenotypic variability in Engelmanndisease (ED): areED andRibbing
disease the same entity? Am J Med Genet. 2000;91:153–156.
8. Aggarwal P, Wali JP, Sharma SK. Progressive diaphyseal dysplasia:
case report and literature review. Orthopedics. 1990;13:901–904.
9. Nishimura G, Nishimura H, Tanaka Y, et al. Camurati-Engelmann
disease type II: progressive diaphyseal dysplasia with striations of
the bones. Am J Med Genet. 2002;107:5–11.
10. Lennon EA, Schechter MM, Hornabrook RW. Engelmann’s Disease:
report of a case with a review of the literature. J Bone Joint Surg.
1961;43B:273–284.
11. Kaftori JK, Kleinhaus U, Naveh Y. Progressive diaphyseal dysplasia
(Camurati-Engelmann): radiographicfollow-upandCT findings. Radi-
ology. 1987;164:777–782.
12. Hanson W, Parnes LS. Vestibular nerve compression in Camurati-
Engelmann disease. Ann Otol Rhinol Laryngol. 1995;104:823–825.
13. Beighton P, Cremin BJ. Sclerosing Bone Dysplasias. Berlin: Springer-
Verlag; 1980.
14. Wright M, Miller NR, McFadzean RM, et al. Papilloedema, a complica-
tion of progressive diaphyseal dysplasia: a series of three case
reports. Br J Ophthalmol. 1998;82:1042–1048.
15. ClawsonDK,LoopJW.Progressivediaphysealdysplasia(Engelmann’s
disease). J Bone Joint Surg Am. 1964;46:143–150.
16. Gupta S, Cheikh IE. Camurati-Engelmann disease in conjunction with
hypogonadism. Endocr Pract. 2005;11:399–407.
17. Crisp AJ, Brenton DP. Engelmann’s disease of bone — a systemic
disorder? Ann Rheum Dis. 1982;41:183–188.
18. Paul LW. Hereditary multiple diaphyseal sclerosis (Ribbing).
Radiology. 1953;60:412–416.
CAMURATI-ENGELMANN DISEASE Journal of Bone and Mineral Research 93119. Smith R, Walton RJ, Corner BD, Gordon IR. Clinical and biochemical
studies in Engelmann’s disease (progressive diaphyseal dysplasia).
Q J Med. 1977;46:273–294.
20. Greenspan A. Sclerosing bone dysplasias — a target-site approach.
Skeletal Radiol. 1991;20:561–583.
21. Vanhoenacker FM, Janssens K, Van Hul W, Gershoni-Baruch R, Brik R,
De Schepper AM. Camurati-Engelmann disease. Review of radio-
clinical features. Acta Radiol. 2003;44:430–434.
22. Byanyima RK, Nabawesi JB. Camurati-Engelmann’s disease: a case
report. Afr Health Sci. 2002;2:118–120.
23. Brat HG, Hamoir X, Matthijs P, Lambin P, Van Campenhoudt M.
Camurati-Engelmann disease: a late and sporadic case with meta-
physeal involvement. Eur Radiol. 1999;9:159–162.
24. Huygen PL, Cremers CW, Verhagen WI, Joosten FB. Camurati-
Engelmanndiseasepresentingas ‘‘juvenileotosclerosis.’’Int J Pediatr
Otorhinolaryngol. 1996;37:129–141.
25. Kormas N, Diamond T, Shnier R. Camurati-Engelmann disease:
Two case reports describing metadiaphyseal dysplasia asso-
ciated with cerebellar ataxia. J Bone Miner Res. 1998;13:1203–
1207.
26. Castro GR, Appenzeller S, Marques-Neto JF, Be ´rtolo MB, Samara AM,
Coimbra I. Camurati-Engelmann disease: failure of response to
bisphosphonates: Report of two cases. Clin Rheumatol. 2005;24:
398–401.
27. Bondestam J, Ma ¨yra ¨npa ¨a ¨ MK, Ikegawa S, Marttinen E, Kro ¨ger H,
Ma ¨kitie O. Bone biopsy and densitometry findings in a child
with Camurati-Engelmann disease. Clin Rheumatol. 2007;26:1773–
1777.
28. Lundy MM, Billingsley JL, Redwine MD, Turnbull GL, Brown TJ.
Scintigraphic findings in progressive diaphyseal dysplasia. J Nucl
Med. 1982;23:324–325.
29. Shuke N, Takashio T, Yamamoto W, et al. Bone scintigraphy in a
patient with progressive diaphyseal dysplasia. Clin Nucl Med.
1997;22:791–792.
30. JanssensK, VanhoenackerF, BonduelleM, et al.Camurati-Engelmann
disease: review of the clinical, radiological, and molecular data of 24
families and implications for diagnosis and treatment. J Med Genet.
2006;43:1–11.
31. Kumar B, Murphy WA, Whyte MP. Progressive diaphyseal dysplasia
(Engelmann disease): scintigraphic-radiographic-clinical correlations.
Radiology. 1981;140:87–92.
32. Clybouw C, Desmyttere S, Bonduelle M, Piepsz A. Camurati-Engel-
mann disease: contribution of bone scintigraphy to genetic counsel-
ing. Genet Couns. 1994;5:195–198.
33. D’Addabbo A, Macarini L, Rubini G, Rubini D, Salzillo F, Lauriero F.
Correlation between bone imaging and the clinical picture in two
unsuspected cases of progressive diaphyseal dysplasia (Engelmann’s
disease). Clin Nucl Med. 1993;18:324–328.
34. Fallon MD, Whyte MP, Murphy WA. Progressive diaphyseal dysplasia
(Engelmann’s disease). Report of a sporadic case of the mild form.
J Bone Joint Surg Am. 1980;62:465–472.
35. Herna ´ndez MV, Peris P, Guan ˜abens N, et al. Biochemical markers of
boneturnoverinCamurati-Engelmanndisease:areportonfourcases
in one family. Calcif Tissue Int. 1997;61:48–51.
36. Naveh Y, Alon U, Kaftori JK, Berant M. Progressive diaphyseal dys-
plasia: evaluation of corticosteroid therapy. Pediatrics. 1985;75:321–
323.
37. Bas ¸ F, Darendeliler F, Petorak I, et al. Deflazacort treatment in
progressive diaphyseal dysplasia (Camurati-Engelmann disease.
J Paediatr Child Health. 1999;35:401–405.
38. Bourantas K, Tsiara S, Drosos AA. Successful treatment with corti-
costeroid in a patient with progressive diaphyseal dysplasia. Clin
Rheumatol. 1995;14:485–486.
39. Low LC, Stephenson JB, Stuart-Smith DA. Progressive diaphyseal
dysplasia mimicking childhood myopathy: clinical and biochemical
response to prednisolone. Aust Paediatr J. 1985;21:193–196.
40. Allen DT, Saunders AM, Northway WH Jr, Williams GF, Schafer IA.
Corticosteroids in the treatment of Engelmann’s disease: progressive
diaphyseal dysplasia. Pediatrics. 1970;46:523–531.
41. Iba K, Takada J, Kamasaki H, et al. A significant improvement in lower
limb pain after treatment with alendronate in two cases of Camurati-
Engelmann disease. J Bone Miner Metab. 2008;26:107–109.
42. Inaoka T, Shuke N, Sato J, et al. Scintigraphic evaluation of pami-
dronate and corticosteroid therapy in a patient with progressive
diaphyseal dysplasia (Camurati-Engelmann disease). Clin Nucl Med.
2001;26:680–682.
43. Kinoshita A, Saito T, Tomita H, et al. Domain-specific mutations in
TGFB1 result in Camurati-Engelmann disease. Nat Genet. 2000;26:
19–20.
44. Janssens K, Gershoni-Baruch R, Guan ˜abens N, et al. Mutations in the
gene encoding the latency-associated peptide of TGF-beta 1 cause
Camurati-Engelmann disease. Nat Genet. 2000;26:273–275.
45. Hecht JT, Blanton SH, Broussard S, Scott A, Hall RC, Milunsky JM.
Evidence for locus heterogeneity in the Camurati-Engelmann (DPD1)
syndrome. Clin Genet. 2001;59:198–200.
46. Whyte MP, Kempa L, McAlister WH, Zhang F, Mumm S, Wenkert D.
Elevated serum lactate dehydrogenase isoenzymes and aspartate
transaminase distinguish Albers-Scho ¨nberg disease (chloride chan-
nel 7 deficiency osteopetrosis) among the sclerosing bone disorders.
J Bone Miner Res. 2010;25:2515–2526.
47. Whyte MP. Paget’s disease of bone and genetic disorders of RANKL/
OPG/RANK/NF-kappaB signaling. Ann N Y Acad Sci. 2006;1068:143–
164.
48. Hughes AE, Ralston SH, Marken J, et al. Mutations in TNFRSF11A,
affecting the signal peptide sequence of RANK, cause familial
expansile osteolysis. Nat Genet. 2000;24:45–48.
49. Rickels M, Zhang X, Mumm S, Whyte MP. Oropharyngeal skeletal
disease accompanying high bone mass and novel LRP5 mutation.
J Bone Miner Res. 2005;20:878–885.
50. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin
deficiency and juvenile Paget’s disease. N Engl J Med. 2002;347:
175–184.
51. Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human
osteopetrosis due to mutations in the gene encoding RANKL. Nat
Genet. 2007;39:960–962.
52. Matucci-Cerinic M, Lotti T, Jajic I, Pignone A, Bussani C, Cagnoni M.
The clinical spectrum of pachydermoperiostosis (primary hyper-
trophic osteoarthropathy). Medicine (Baltimore). 1991;70:208–
214.
53. Uppal S, Diggle CP, Carr IM, et al. Mutations in 15-hydroxyprosta-
glandin dehydrogenase cause primary hypertrophic osteoarthropa-
thy. Nat Genet. 2008;40:789–793.
54. National Center for Biotechnology Information. Single nucleotide
polymorphism database, http://www.ncbi.nlm.nih.gov/sites/entrez?
db¼snp Last accessed: April 27, 2010.
55. Xiong DH, Shen H, Zhao LJ, et al. Robust and comprehensive analysis
of 20 osteoporosis candidate genes by very high-density single-
nucleotide polymorphism screen among 405 white nuclear families
identified significant association and gene-gene interaction. J Bone
Miner Res. 2006;21:1678–1695.
56. Hsu YH, Niu T, Terwedow HA, et al. Variation in genes involved in the
RANKL/RANK/OPG bone remodeling pathway are associated with
bone mineral density at different skeletal sites in men. Hum Genet.
2006;118:568–577.
57. Soedarsono N, Rabello D, Kamei H, et al. Evaluation of RANK/RANKL/
OPG gene polymorphisms in aggressive periodontitis. J Periodontal
Res. 2006;41:397–404.
932 Journal of Bone and Mineral Research WHYTE ET AL.58. WhyteMP,WenkertD,McAlisterWH,NovackD,NenningerAR,Zhang
X, Huskey M, Mumm S. Dysosteosclerosis presents as an ‘‘osteoclast-
poor’’ form of osteopetrosis: Comprehensive investigation of a 3-
year-old girl and literature review. J Bone Miner Res. 2010;25:2527–
2539.
59. Ballardini P, Gulmini L, Margutti G, Lelli G. Mesenteric fibromatosis in
a patient with Camurati-Engelmann disease. A case report and
literature review. Tumori. 2005;91:552–554.
60. Higashi K, Matsuki C. Hearing impairment in Engelmann disease.
Am J Otol. 1996;17:26–29.
61. Hoeffel JC, Mainard L, Leyder B. Camurati-Engelmann disease. A case
report. Eur Radiol. 1999;9:1932–1933.
62. Grey AC, Wallace R, Crone M. Engelmann’s disease: a 45-year follow-
up. J Bone Joint Surg Br. 1996;78:488–491.
63. Singleton EB, Thomas JR, Worthington WW, Hild JR. Progressive
diaphyseal dysplasia (Engelmann’s disease). Radiology. 1956;67:
233–241.
64. Sparkes RS, Graham CB. Camurati-Engelmann disease. Genetics and
clinical manifestations with a review of the literature. J Med Genet.
1972;9:73–85.
65. Simsek S, Janssens K, Kwee ML, Van Hul W, Veenstra J, Netelenbos JC.
Camurati-Engelmann disease (progressive diaphyseal dysplasia) in a
Moroccan family. Osteoporos Int. 2005;16:1167–1170.
66. Saraiva JM. Progressive diaphyseal dysplasia: a three-generation
family with markedly variable expressivity. Am J Med Genet.
1997;71:348–352.
67. ReillyBM,HartPD,MascarellS,ChatrathH.Clinicalproblem-solving.A
question well put. N Engl J Med. 2009;360:1446–1451.
68. Campos-Xavier B, Saraiva JM, Savarirayan R, et al. Phenotypic varia-
bility at the TGF-beta1 locus in Camurati-Engelmann disease. Hum
Genet. 2001;109:653–658.
69. Saraiva JM. Anticipation in progressive diaphyseal dysplasia. J Med
Genet. 2000;37:394–395.
70. Fujimoto H, Nishimura G, Tsumurai Y, et al. Hyperostosis generalisata
with striations of the bones: report of a female case and a review of
the literature. Skeletal Radiol. 1999;28:460–464.
71. Janssens K, ten Dijke P, Ralston SH, Bergmann C, Van Hul W.
Transforming growth factor-beta 1 mutations in Camurati-Engel-
manndiseaseleadtoincreasedsignalingbyalteringeitheractivation
or secretion of the mutant protein. J Biol Chem. 2003;278:7718–7724.
72. Yan T, Riggs BL, Boyle WJ, Khosla S. Regulation of osteoclastogenesis
andRANKexpressionbyTGF-beta1.JCellBiochem.2001;83:320–325.
73. Quinn JM, Itoh K, Udagawa N, et al. Transforming growth factor beta
affects osteoclast differentiation via direct and indirect actions.
J Bone Miner Res. 2001;16:1787–1794.
74. Saito T, Kinoshita A, Yoshiura Ki, et al. Domain-specific mutations of a
transforming growth factor (TGF)-beta 1 latency-associated peptide
cause Camurati-Engelmann disease because of the formation of a
constitutively active form of TGF-beta 1. J Biol Chem. 2001;276:
11469–11472.
75. McGowan NW, MacPherson H, Janssens K, et al. A mutation affecting
the latency-associated peptide of TGFbeta1 in Camurati-Engelmann
disease enhances osteoclast formation in vitro. J Clin Endocrinol
Metab. 2003;88:3321–3326.
76. Massague ´ J, Cheifetz J, Endo T, Nadal-Ginard B. Type beta transform-
ing growth factor is an inhibitor of myogenic differentiation. Proc
Natl Acad Sci USA. 1986;83:8206–8210.
77. Ignotz RA, Massague ´ J. Type beta transforming growth factor con-
trols the dipogenic differentiation of 3T3 fibroblasts. Proc Natl Acad
Sci USA. 1985;82:8530–8534.
78. Genevieve D, Proulle V, Isidor B, et al. Thromboxane synthase
mutations in an increased bone density disorder (Ghosal syndrome).
Nat Genet. 2008;40:284–286.
79. Ghosal SP, Mukherjee AK, Mukherjee D, Ghosh AK. Diaphyseal
dysplasia associated with anemia. J Pediatr. 1988;113:49–57.
80. Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL.
Structural basis for the binding of proline-rich peptides to SH3
domains. Cell. 1994;76:933–945.
81. Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L, Debussche L.
The requirement for the p53 proline-rich functional domain for
mediation of apoptosis is correlated with specific PIG3 gene trans-
activation and with transcriptional repression. EMBO J. 1998;17:
4668–4679.
CAMURATI-ENGELMANN DISEASE Journal of Bone and Mineral Research 933